Neuroprotective effect and potential of cellular prion protein and its cleavage products for treatment of neurodegenerative disorders part II: strategies for therapeutics development

References

• Riek R, Hornemann S, Wider G, et al. NMR structure of the mouse prion protein domain PrP(121–231). Nature. 1996;382(6587):180–182.
   PubMed Web of Science ®Google Scholar
• Zahn R, Liu A, Lührs T, et al. NMR solution structure of the human prion protein. Proc Natl Acad Sci U S A. 2000;97(1):145–501227–1235.
   Web of Science ®Google Scholar
• Adle-Biassette H, Verney C, Peoc’h K, et al. Immunohistochemical Expression of Prion Protein (PrPC) in the Human Forebrain During Development. J Neuropathol Exp Neurol. 2006;65(7):698–706.
   PubMed Web of Science ®Google Scholar
• Peralta OA, Eyestone WH. Quantitative and qualitative analysis of cellular prion protein (PrP(C)) PrP C) expression in bovine somatic tissues. Prion. 2009;3(3):161–170.
   PubMed Web of Science ®Google Scholar
• Castle AR, Gill AC. Physiological Functions of the Cellular Prion Protein. Front Mol Biosci. 2017;6;4:19.
   Web of Science ®Google Scholar
• Linden R. The Biological Function of the Prion Protein: a Cell Surface Scaffold of Signaling Modules. Front Mol Neurosci. 2017;10:77.
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Heikenwalder M. Pathogenesis of prion diseases: current status and future outlook. Nat Rev Microbiol. 2006;4(10):765–775.
   PubMed Web of Science ®Google Scholar
• Colby DW, Prusiner SB. Prions. Cold Spring Harb Perspect Biol. 2011;3(1):a006833.
   PubMed Web of Science ®Google Scholar
• Sigurdson CJ, Bartz JC, Cellular GM. Molecular Mechanisms of Prion Disease. Annu Rev Pathol. 2019 Jan 24;14(1):497–516.
   PubMed Web of Science ®Google Scholar
• Laurén J, Gimbel DA, Nygaard HB, et al. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009;457(7233): 1128–1132.
   PubMed Web of Science ®Google Scholar
• Um JW, Nygaard HB, Heiss JK, et al. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci. 2012;15(9):1227–1235.
   PubMed Web of Science ®Google Scholar
• Haas LT, Salazar SV, Kostylev MA, et al. Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer’s disease. Brain. 2016;139(2):526–546.
   PubMed Web of Science ®Google Scholar
• Aulić S, Masperone L, Narkiewicz J, et al. α-Synuclein amyloids hijack prion protein to gain cell entry, facilitate cell-to-cell spreading and block prion replication. Sci Rep. 2017;7(1):10050.
   PubMed Web of Science ®Google Scholar
• Salazar SV, Strittmatter SM. Cellular prion protein as a receptor for amyloid-β oligomers in Alzheimer’s disease. Biochem Biophys Res Commun. 2017;483(4):1143–1147.
   PubMed Web of Science ®Google Scholar
• Shafiei SS, Guerrero-Muñoz MJ, Castillo-Carranza DL. Tau Oligomers: cytotoxicity, Propagation, and Mitochondrial Damage. Front Aging Neurosci. 2017;9:83.
   PubMed Web of Science ®Google Scholar
• Urrea L, Segura-Feliu M, Masuda-Suzukake M, et al. Involvement of Cellular Prion Protein in α-Synuclein Transport in Neurons. Mol Neurobiol. 2018;55:60–1847.
   Google Scholar
• Corbett GT, Wang Z, Hong W, et al. Young-Pearse TL, Billinton A, Walsh DM. PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins. Acta Neuropathol. 2020;139(3): 503–526.
   PubMed Web of Science ®Google Scholar
• Pan Y, Zhao L, Liang J, et al. Cellular prion protein promotes invasion and metastasis of gastric cancer. FASEB J. 2006;20(11):1886–1888.
   PubMed Web of Science ®Google Scholar
• Han H, Bearss DJ, Browne LW, et al. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 2002;62:2890–2896.
   PubMed Web of Science ®Google Scholar
• Li C, Yu S, Nakamura F, et al. Binding of pro-prion to filamin A disrupts cytoskeleton and correlates with poor prognosis in pancreatic cancer. J Clin Invest. 2009;119(9):2725–2736.
   PubMed Web of Science ®Google Scholar
• Sy MS, Li C, Yu S, et al. The fatal attraction between pro-prion and filamin A: prion as a marker in human cancers. Biomark Med. 2010;4(3):453–464.
   PubMed Web of Science ®Google Scholar
• Antony H, Wiegmans AP, Wei MQ, et al. Potential roles for prions and protein-only inheritance in cancer. Cancer Metastasis Rev. 2012;31(1–2):1–19.
   PubMed Web of Science ®Google Scholar
• Bremer J, Baumann F, Tiberi C, et al. Axonal prion protein is required for peripheral myelin maintenance. Nat Neurosci. 2010;13(3):310–83204–3210.
   PubMed Web of Science ®Google Scholar
• Chiarini LB, Freitas AR, Zanata SM, et al. Cellular prion protein transduces neuroprotective signals. EMBO J. 2002;21(13):3317–263101–3103.
   Web of Science ®Google Scholar
• Chen S, Mangé A, Dong L, et al. Prion protein as trans-interacting partner for neurons is involved in neurite outgrowth and neuronal survival. Mol Cell Neurosci. 2003;22(2):227–233.
   PubMed Web of Science ®Google Scholar
• Lopes MH, Hajj GN, Muras AG, et al. Interaction of cellular prion and stress-inducible protein 1 promotes neuritogenesis and neuroprotection by distinct signaling pathways. J Neurosci. 2005;25(49):11330–11339.
   PubMed Web of Science ®Google Scholar
• Dexter E, Kong Q. Neuroprotective effect and potential of cellular prion protein and its cleavage products for treatment of neurodegenerative disorders. Part I. A literature review. Expert Rev Neurother. 2021;21(9):969–982.
   Web of Science ®Google Scholar
• Chen SG, Teplow DB, Parchi P, et al. Truncated forms of the human prion protein in normal brain and in prion diseases. J Biol Chem. 1995;270(32):19173–8010238–10243.
   Web of Science ®Google Scholar
• Cissé MA, Sunyach C, Lefranc-Jullien S, et al. The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity. J Biol Chem. 2005;280(49):40624–40631.
   PubMed Web of Science ®Google Scholar
• Taylor DR, Parkin ET, Cocklin SL, et al. Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein. J Biol Chem. 2009;284(34):22590–22600.
   PubMed Web of Science ®Google Scholar
• Vincent B, Paitel E, Saftig P, et al. The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. J Biol Chem. 2001;276(41):37743–37746.
   PubMed Web of Science ®Google Scholar
• Altmeppen HC, Prox J, Puig B, et al. Lack of a-disintegrin-and-metalloproteinase ADAM10 leads to intracellular accumulation and loss of shedding of the cellular prion protein in vivo. Mol Neurodegener. 2011;6(1): 36.
   PubMed Web of Science ®Google Scholar
• Liang J, Kong Q. α-Cleavage of cellular prion protein. Prion. 2012a;6(5):453–460.
   PubMed Web of Science ®Google Scholar
• Liang J, Wang W, Sorensen D, et al. Cellular prion protein regulates its own α-cleavage through ADAM8 in skeletal muscle. J Biol Chem. 2012b;287(20):16510–16520.
   PubMed Web of Science ®Google Scholar
• McDonald AJ, Dibble JP, Evans EG, et al. A new paradigm for enzymatic control of α-cleavage and β-cleavage of the prion protein. J Biol Chem. 2014b;289(2):803–813.
   PubMed Web of Science ®Google Scholar
• Guillot-Sestier MV, Sunyach C, Druon C, et al. The alpha-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo. J Biol Chem. 2009;284(51): 35973–35986.
   PubMed Web of Science ®Google Scholar
• Guillot-Sestier MV, Sunyach C, Ferreira ST, et al. α-Secretase-derived fragment of cellular prion, N1, protects against monomeric and oligomeric amyloid β (Aβ)-associated cell death. J Biol Chem. 2011;287(7):5021–5032.
   PubMed Web of Science ®Google Scholar
• Fluharty BR, Biasini E, Stravalaci M, et al. An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo. J Biol Chem. 2013;288(11): 7857–7866.
   PubMed Web of Science ®Google Scholar
• Béland M, Bédard M, Tremblay G, et al. Aβ induces its own prion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphous aggregates. Neurobiol Aging. 2014a;35(7):1537–481886–1888.
   PubMed Web of Science ®Google Scholar
• Scott-McKean JJ, Surewicz K, Choi JK, et al. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: implications for novel therapeutic strategy in Alzheimer’s disease. Neurobiol Dis. 2016;91:124–131.
   PubMed Web of Science ®Google Scholar
• Westergard L, Turnbaugh JA, Harris DA. A naturally occurring C-terminal fragment of the prion protein (PrP) delays disease and acts as a dominant-negative inhibitor of PrPSc formation. J Biol Chem. 2011;286(51):44234–44242.
   PubMed Web of Science ®Google Scholar
• Sunyach C, Cisse MA, Da Costa CA, et al. The C-terminal products of cellular prion protein processing, C1 and C2, exert distinct influence on p53-dependent staurosporine -induced caspase-3 activation. J Biol Chem. 2007;282(3):1956–1963.
   PubMed Web of Science ®Google Scholar
• Huang S, Liang J, Zheng M, et al. Regulated over-expression of PrP in the skeletal muscles leads to myopathy in transgenic mice. Proc Natl Acad Sci USA. 2007;104(16):6800–6805.
   PubMed Web of Science ®Google Scholar
• Liang J, Parchaliuk D, Medina S, et al. Activation of p53-regulated pro-apoptotic signaling pathways in PrP-mediated myopathy. BMC Genomics. 2009;10(1):201.
   PubMed Web of Science ®Google Scholar
• Kanaani J, Prusiner SB, Diacovo J, et al. Recombinant prion protein induces rapid polarization and development of synapses in embryonic rat hippocampal neurons in vitro. J Neurochem. 2005;95(5):1373–1386.
   PubMed Web of Science ®Google Scholar
• Amin L, Xuan TA, Nguyen Rolle IG, et al. Characterization of prion protein function by focal neurite stimulation. Cell Sci. 2016;129:3878–3891.
   PubMed Web of Science ®Google Scholar
• Nieznanski K, Choi JK, Chen S, et al. Soluble prion protein inhibits amyloid-β (Aβ) fibrillization and toxicity. J Biol Chem. 2012;287(40):33104–811330–11339.
   Web of Science ®Google Scholar
• Calella AM, Farinelli M, Nuvolone M, et al. Prion protein and Abeta-related synaptic toxicity impairment. EMBO Mol Med. 2010;2(8):306–1419173–19180.
   PubMed Web of Science ®Google Scholar
• Tagliavini F, Prelli F, Porro M, et al. A soluble form of prion protein in human cerebrospinal fluid: implications for prion-related encephalopathies. Biochem Biophys Res Commun. 1992;184(3):1398–1404.
   PubMed Web of Science ®Google Scholar
• Borchelt DR, Rogers M, Stahl N, et al. Release of the cellular prion protein from cultured cells after loss of its glycoinositol phospholipid anchor. Glycobiology. 1993;3(4):319–329.
   PubMed Web of Science ®Google Scholar
• Parizek P, Roeckl C, Weber J, et al. Similar turnover and shedding of the cellular prion protein in primary lymphoid and neuronal cells. J Biol Chem. 2001;276(48):44627–44632.
   PubMed Web of Science ®Google Scholar
• McDonald AJ, Millhauser GL. PrP overdrive: does inhibition of α-cleavage contribute to PrP(C) toxicity and prion disease? Prion. 2014;8(2):183–191
   Web of Science ®Google Scholar
• Heiseke A, Schöbel S, Lichtenthaler SF, et al. The Novel Sorting Nexin SNX33 Interferes with Cellular PrPSc PrP Sc Formation by Modulation of PrPc PrPc Shedding. Traffic. 2008;9(7):1116–1129.
   PubMed Web of Science ®Google Scholar
• Endres K, Mitteregger G, Kojro E, et al. Influence of ADAM10 on prion protein processing and scrapie infectiosity in vivo. Neurobiol Dis. 2009;36(2):233–4137743–37746.
   PubMed Web of Science ®Google Scholar
• Watts JC, Giles K, Patel S, et al. Evidence that bank vole PrP is a universal acceptor for prions. PLoS Pathog. 2014;10:e1003990.
   PubMed Web of Science ®Google Scholar
• Altmeppen HC, Prox J, Krasemann S, et al. The sheddase ADAM10 is a potent modulator of prion disease. eLife. 2015;4:e04260.
   Web of Science ®Google Scholar
• An K, Klyubin I, Kim YJ, et al. Exosomes neutralize synaptic-plasticity-disrupting activity of Aβ assemblies in vivo. Mol Brain. 2013;6:47.
   PubMed Web of Science ®Google Scholar
• Falker C, Hartmann A, Guett I, et al. Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity. J Neurochem. 2016;137(1): 88–100.
   PubMed Web of Science ®Google Scholar
• Yuyama K, Sun H, Sakai S, et al. Decreased Amyloid-beta Pathologies by Intracerebral Loading of Glycosphingolipid-enriched Exosomes in Alzheimer Model Mice. J Biochem. 2014;289:24488–24498.
   Google Scholar
• Legname G, Scialò C. On the role of the cellular prion protein in the uptake and signaling of pathological aggregates in neurodegenerative diseases. Prion. 2020;14(1):257–270.
   PubMed Web of Science ®Google Scholar
• Béland M, Roucou X. Taking advantage of physiological proteolytic processing of the prion protein for a therapeutic perspective in prion and Alzheimer diseases. Prion. 2014;8(1):106–110.
   PubMed Web of Science ®Google Scholar
• Nieznanska H, Bandyszewska M, Surewicz K, et al. Identification of prion protein-derived peptides of potential use in Alzheimer’s disease therapy. Biochim Biophys Acta. 2018;1864(6):2143–2153.
   Web of Science ®Google Scholar
• Mohammadi B, Linsenmeier L, Shafiq M, et al. Transgenic overexpression of the disordered prion Protein N1 fragment in mice does not protect against neurodegenerative diseases due to impaired er translocation. Mol Neurobiol. 2020;57(6):2812–2829.
   PubMed Web of Science ®Google Scholar
• Mohammadi B, Glatzel M, Altmeppen HC. Disordered structure and flexible roles: using the prion protein N1 fragment for neuroprotective and regenerative therapy. Neural Regen Res. 2021;16(7):1431–1432.
   PubMed Web of Science ®Google Scholar
• Müller MM. Post-Translational Modifications of Protein Backbones: unique Functions, Mechanisms, and Challenges. Biochemistry. 2018;57:177–185.
   PubMed Web of Science ®Google Scholar
• Fisher E, Pavlenko K, Vlasov A, et al. Peptide-Based Therapeutics for Oncology. Pharmaceut Med. 2019;33:9–20.
   PubMed Web of Science ®Google Scholar
• Ding Y, Jp T, Liu J, et al. Impact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics. Amino Acids. 2020;52(9):1207–1226.
   PubMed Web of Science ®Google Scholar
• San Sebastian W, Samaranch L, Kells AP, et al. Gene therapy for misfolding protein diseases of the central nervous system. Neurotherapeutics. 2013;10(3):498–510.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Stanek LM, Ohno K, et al. Extensive Transduction and Enhanced Spread of a Modified AAV2 Capsid in the Non-human Primate CNS. Mol Ther. 2018;26(10):2418–2430.
   PubMed Web of Science ®Google Scholar
• Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358–378.
   PubMed Web of Science ®Google Scholar
• Vincent B, Paitel E, Frobert Y, et al. Phorbol ester-regulated cleavage of normal prion protein in HEK293 human cells and murine neurons. J Biol Chem. 2000;275(45):35612–35616.
   PubMed Web of Science ®Google Scholar
• Lammich S, Kojro E, Postina R, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA. 1999;96(7): 3922–3927.
   PubMed Web of Science ®Google Scholar
• Kuhn PH, Wang H, Dislich B, et al. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J. 2010;29(17):3020–3032.
   PubMed Web of Science ®Google Scholar
• Postina R, Schroeder A, Dewachter I, et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest. 2004;113(10): 1456–643922–3927.
   PubMed Web of Science ®Google Scholar
• Prinzen C, Trümbach D, Wurst W, et al. Differential gene expression in ADAM10 and mutant ADAM10 transgenic mice. BMC Genomics. 2009;10(1):66.
   PubMed Web of Science ®Google Scholar
• Clement AB, Hanstein R, Schröder A, et al. Effects of neuron-specific ADAM10 modulation in an in vivo model of acute excitotoxic stress. Neuroscience. 2008;152(2):459–468.
   PubMed Web of Science ®Google Scholar
• Mullooly M, McGowan PM, Crown J, et al. The ADAMs family of proteases as targets for the treatment of cancer. Cancer Biol Ther. 2016;17(8):870–801456–1464.
   PubMed Web of Science ®Google Scholar
• Smith TM Jr, Tharakan A, Martin RK. Targeting ADAM10 in Cancer and Autoimmunity. Front Immunol. 2020;11:499.
   PubMed Web of Science ®Google Scholar
• Dreymueller D, Pruessmeyer J, Groth E, et al. The role of ADAM-mediated shedding in vascular biology. Eur J Cell Biol. 2012;91(6–7):472–485.
   PubMed Web of Science ®Google Scholar
• Conrad C, Benzel J, Dorzweiler K, et al. ADAM8 in invasive cancers: links to tumor progression, metastasis, and chemoresistance. Clin Sci (Lond). 2019;133(1):83–99.
   PubMed Web of Science ®Google Scholar
• Tousseyn T, Thathiah A, Jorissen E, et al. ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase. J Biol Chem. 2009;284(17):11738–11747.
   PubMed Web of Science ®Google Scholar
• Matthews AL, Noy PJ, Reyat JS, et al. Regulation of A disintegrin and metalloproteinase (ADAM) family sheddases ADAM10 and ADAM17: the emerging role of tetraspanins and rhomboids. Platelets. 2017;28(4):333–341.
   PubMed Web of Science ®Google Scholar
• Béland M, Motard J, Barbarin A, et al. PrP(C) homodimerization stimulates the production of PrPC cleaved fragments PrPN1 and PrPC1. J Neurosci. 2012;32(38):13255–13263.
   PubMed Web of Science ®Google Scholar
• Meier P, Genoud N, Prinz M, et al. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease. Cell. 2003;113(1):49–60.
   PubMed Web of Science ®Google Scholar
• Engelke AD, Gonsberg A, Thapa S, et al. Dimerization of the cellular prion protein inhibits propagation of scrapie prions. J Biol Chem. 2018;293(21):8020–8031.
   PubMed Web of Science ®Google Scholar
• Dai J, Liu ZQ, Wang XQ, et al. Discovery of Small Molecules for Up-Regulating the Translation of Antiamyloidogenic Secretase, a Disintegrin and Metalloproteinase 10 (ADAM10), by Binding to the G-Quadruplex-Forming Sequence in the 5’ Untranslated Region (UTR) of Its mRNA. J Med Chem. 2015;58(9):3875–3891.
   PubMed Web of Science ®Google Scholar
• Wetzel S, Seipold L, Saftig P. The metalloproteinase ADAM10: a useful therapeutic target? Biochim Biophys Acta Mol Cell Res. 2017;1864(11):2071–2081.
   PubMed Web of Science ®Google Scholar
• Yuyama K, Sun H, Usuki S, et al. A potential function for neuronal exosomes: sequestering intracerebral amyloid-beta peptide. FEBS Lett. 2015;589(1): 84–88.
   PubMed Web of Science ®Google Scholar
• Yang T, Martin P, Fogarty B, et al. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in danio rerio. Pharm Res. 2015;32(6):2003–2014.
   PubMed Web of Science ®Google Scholar
• Chen C, Liu L, Ma F, et al. Elucidation of Exosome Migration Across the Blood–Brain Barrier Model In Vitro. Cell Mol Bioeng. 2016;9(4):509–529.
   PubMed Web of Science ®Google Scholar
• Li X, Corbett AL, Taatizadeh E, et al. Challenges and opportunities in exosome research-Perspectives from biology, engineering, and cancer therapy. APL Bioeng. 2019;3(1):011503.
   PubMed Web of Science ®Google Scholar
• Jafari D, Shajari S, Jafari R, et al. Designer Exosomes: a New Platform for Biotechnology Therapeutics. BioDrugs. 2020;34(5):567–586.
   PubMed Web of Science ®Google Scholar
• Song H, Liu B, Dong B, et al. Exosome-Based Delivery of Natural Products in Cancer Therapy. Front Cell Dev Biol. 2021;9:650426.
   PubMed Web of Science ®Google Scholar
• Alvarez-Erviti L, Seow Y, Yin H, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341–345.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Mahmood A, Chopp M. Emerging potential of exosomes for treatment of traumatic brain injury. Neural Regen Res. 2017;12(1):19–22.
   PubMed Web of Science ®Google Scholar
• Stam J, Bartel S, Bischoff R, et al. Isolation of extracellular vesicles with combined enrichment methods. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1169:122604.
   PubMed Web of Science ®Google Scholar
• Kurian TK, Banik S, Gopal D, et al. Elucidating Methods for Isolation and Quantification of Exosomes: a Review. Mol Biotechnol. 2021;63(4):249–266.
   PubMed Web of Science ®Google Scholar
• Gao B, Zhou S, Sun C, et al. Brain Endothelial Cell-Derived Exosomes Induce Neuroplasticity in Rats with Ischemia/Reperfusion Injury. ACS Chem Neurosci. 2020;11(15):2201–2213.
   PubMed Web of Science ®Google Scholar
• Tu YK, Hsueh YH. Extracellular vesicles isolated from human olfactory ensheathing cells enhance the viability of neural progenitor cells. Neurol Res. 2020;42(11):959–672201–2213.
   PubMed Web of Science ®Google Scholar
• Maia J, Caja S, Strano Moraes MC, et al. Exosome-based cell-cell communication in the tumor microenvironment. Front Cell Dev Biol. 2018;6:18.
   PubMed Web of Science ®Google Scholar
• Emmanouilidou E, Melachroinou K, Roumeliotis T, et al. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci. 2010;30(20):6838–6851.
   PubMed Web of Science ®Google Scholar
• Hu G, Yao H, Chaudhuri AD, et al. Exosome-mediated shuttling of microRNA-29 regulates HIV Tat and morphine-mediated neuronal dysfunction. Cell Death Dis. 2012;3(8):e381–10.
   PubMed Web of Science ®Google Scholar
• Saman S, Kim W, Raya M, et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem. 2012;287(6):3842–3849.
   PubMed Web of Science ®Google Scholar
• Fevrier B, Vilette D, Archer F, et al. Cells release prions in association with exosomes. Proc Natl Acad Sci U S A. 2004;101(26):9683–9688.
   PubMed Web of Science ®Google Scholar
• Vella LJ, Sharples RA, Lawson VA, et al. Packaging of prions intoexosomes is associated with a novel pathway of PrP processing. J Pathol. 2007;211(5):582–590.
   PubMed Web of Science ®Google Scholar
• Cervenakova L, Saa P, Yakovleva O, et al. Are prions transported by plasma exosomes? Transfus Apher Sci. 2016;55(1):70–83.
   PubMed Web of Science ®Google Scholar
• Chesebro B, Trifilo M, Race R, et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science. 2005;308(5727):1435–1439.
   PubMed Web of Science ®Google Scholar
• Chesebro B, Race B, Meade-White K, et al. Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with lack of prion protein membrane anchoring. PLoS Pathog. 2010;6(3):e1000800.
   PubMed Web of Science ®Google Scholar
• Stohr J, Watts JC, Legname G, et al. Spontaneous generation of anchorless prions in transgenic mice. Proc Natl Acad Sci USA. 2011;108(52):21223–21228.
   PubMed Web of Science ®Google Scholar
• Roberts TK, Eugenin EA, Morgello S, et al. PrPC, the cellular isoform of the human prion protein, is a novel biomarker of HIV-associated neurocognitive impairment and mediates neuroinflammation. Am J Pathol. 2010;177(4):1848–1860.
   PubMed Web of Science ®Google Scholar
• Megra BW, Eugenin EA, Berman JW. The Role of Shed PrPcin the Neuropathogenesis of HIV InfectionInfection. J Immunol. 2017;199(1):224–232.
   PubMed Web of Science ®Google Scholar
• Chou CW, Huang YK, Kuo TT, et al. An Overview of ADAM9: structure, activation, and regulation in human diseases. Int J Mol Sci. 2020;21(20):7790.
   Web of Science ®Google Scholar
• Daude N. Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J Cell Sci. 2003;116(13):2775–2779.
   PubMed Web of Science ®Google Scholar
• Pfeifer A, Eigenbrod S, Al-Khadra S, et al. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J Clin Invest. 2006;116(12): 3204–3210.
   PubMed Web of Science ®Google Scholar
• Kong Q. RNAi: a novel strategy for the treatment of prion diseases. J Clin Invest. 2006;116(12):3101–3103.
   PubMed Web of Science ®Google Scholar
• White MD, Farmer M, Mirabile I, et al. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci. 2008;105(29):10238–10243.
   PubMed Web of Science ®Google Scholar
• Pulford B, Reim N, Bell A, et al. Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrPC on neuronal cells and PrPRES in infected cell cultures. PLoS One. 2010;5(6):1–13.
   Web of Science ®Google Scholar
• Onodera T, Sakudo A, Tsubone H, et al. Review of studies that have used knockout mice to assess normal function of prion protein under immunological or pathophysiological stress. Microbiol Immunol. 2014;58(7):361–374.
   PubMed Web of Science ®Google Scholar
• Bender H, Noyes N, Annis JL. PrPC knockdown by liposome-siRNA-peptide complexes (LSPCs) prolongs survival and normal behavior of prion-infected mice immunotolerant to treatment. PLoS One. 2019;14(7):e0219995.
   PubMed Web of Science ®Google Scholar
• Raymond GJ, Zhao HT, Race B, et al. Antisense oligonucleotides extend survival of prion-infected mice. JCI Insight. 2019;54(16):131175.
   Web of Science ®Google Scholar